Sachs-Bloomberg Global Biotech Investor Forum 2003 Exhibitor Profiles.

Business Editors/Biotechnology Writers

Sachs Global Biotech Investor Forum 2003

BOSTON--(BUSINESS WIRE)--Feb. 18, 2003

The Sachs-Bloomberg Global Biotech Investor Forum runs March 20 - 21 at the Fairmont Copley Plaza in Boston. For more information about the event visit http://www.sachsforum.com/global2003_fs.html.

Listed below are profiles from Sachs-Bloomberg Global Biotech Investor Forum presenting companies. News releases and advisories are available at http://www.tradeshownews.com.

Business Wire is the official news service for the Sachs-Bloomberg Global Biotech Investor Forum.

Company:  Aderis Pharmaceuticals
Workshop:  Therapeutics
Media Contact:  Sharon Correia
Phone:  [phone] ext. 224
E-mail: [e-mail]
Company URL:  www.aderis.com

Product description: Aderis concentrates on receptors-subtypes
that mediate the action of adenosine and dopamine and enzymes that are
involved in inflammation. Our programs include Phase III trials for
rotigotine CDS in Parkinson's disease and Phase II in
Restless-Legs-Syndrome, Phase II trials for binodenoson in cardiac
imaging, completion of Phase II trials for DTI-0009 in acute atrial
fibrillation and IIa trials for MRE-0094 in diabetic foot ulcers.

Company description: Aderis Pharmaceuticals is a biopharmaceutical
company engaged in small molecule drug development to treat central
nervous system, cardiovascular and autoimmune/inflammation disorders.
The Company currently has four drug candidates in six clinical
development programs, with its lead program completing Phase III
clinical trials in 2003 for treatment of Parkinson's disease.

Company:   allvivo, Inc.
Workshop:   medical devices
Media Contact:    Dianne Pettey
Investor Relations Contact:   Frank Ahmann
Phone:  [phone]
E-mail:  [e-mail]
Company URL: http://www.allvivo.com

Product description: allvivo develops bio-interactive devices for
critical care medicine, tissue engineering and research. allvivo's
proprietary technology regulates the interaction of biomaterials,
cells, and proteins to elicit a therapeutic response at the device
surface. Products include transient drug-device combination catheters
and filters for critical care, and tissue engineering environments
with recombinant proteins.

Company description: Based in Southern California and founded in
1999, allvivo collaborates domestically with the University of Utah
and internationally with Uppsala and Kalmar Universities (Sweden).
allvivo's growth model provides a balanced portfolio including
partnerships with device companies for drug-device combinations,
direct marketing of tissue engineering systems, and out-licensing of
other bio-interactive applications.

Company:  Angiogene Inc.
Workshop:  Medical Devices
Media Contact:  Susan Baldwin
Investor Relations Contact:  Vincent Taillefer
Phone: [phone]
E-mail:  [e-mail]
Company URL:   www.angiogene.com

Product description: SealantCoil(TM) addresses the unmet medical
need associated with the recanalization of coil-treated aneurysms.
AngioCell(TM) is a combined gene and cell therapy that aims to improve
pump function and perfusion of the diseased heart muscle in patients
suffering from CHF. Both products are scheduled to be in clinical
phase during 2003.

Company description: Angiogene Inc. is a venture-backed, private
biotechnology company focused on the development of innovative
drug-device combinations within the interventional cardiology and
neurovascular fields, which aim to minimize invasive surgical
procedures. Its offices and laboratories are located in Montreal,
Canada, and in operation since 1997.

Company: Aptamera, Inc.
Workshop: Immunology/Oncology
Media Contact: Terry Minton
Investor Relations Contact: Brian Brohman
Phone: [phone]
E-mail: [e-mail]
Company URL: www.aptamera.com

Product description: The Company's diagnostic products focus on
the detection of the cancer marking protein termed nucleolin on cancer
cells, while its drug pipeline consists of novel antiproliferative
agents that bind to nucleolin on cell surfaces, causing cycle arrest
of cancerous cell growth, inhibition of DNA replication, and
initiation of apoptosis, or disintegration of cancer cells.

Company description: Aptamera is a developer of therapeutic and
diagnostic technologies primarily targeting cancer. In mid-2003,
Aptamera's lead drug candidate will enter Phase I Clinical Trials, and
it will launch its first research-use only diagnostic kits aimed at
cervical and lung cancer. The Company will then seek clinical use
indications for its diagnostic kits.

Company: atugen AG
Workshop: Post Genomics Workshop
Media Contact: Thomas Christely
Phone: [phone]
E-mail: [e-mail]
Company URL: www.atugen.com

Product description:
atugen's offers:

--Pipeline of proprietary novel and highly validated cancer targets
and drug candidates

--Elucidation of disease specific signal transduction pathways by
simulating disease progression and observing the cellular changes in
vitro and in vivo

--Drug screening programs (pathway/phenotypic approach and target
based approach)

--Largest set of KnockDown technologies (low toxic GeneBlocs
antisense molecules, stabilized synthetic siRNA, vector expression
systems for siRNA and ribozymes)

--Superior delivery reagents transfecting almost all cell types
(transfection rate greater than 95%)

--Lead compound confirmation and optimization

Company description: atugen AG is a technology leader in disease
pathway elucidation. Building on successful high profile
collaborations, atugen is positioned to take advantage of the
industry's need to unravel the function of genes and to dissect signal
transduction pathways. atugen's in-house target and drug discovery is
supported and endorsed by a profitable, market leading service
business.

Company: Avidex Limited
Workshop: Immunology / Oncology
Investor Relations Contact: James Noble
Phone: [phone]
E-mail: [e-mail]
Company URL: www.avidex.com

Product description:
Avidex's protein and small molecule products include:

--Monoclonal TcRs(TM) that can target anti-cancer agents to tumours or
block activation of T cells in autoimmune diseases.

--An orally active small molecule CD80 antagonist that acts as a
gentle immune suppressor.

Company description: Avidex focuses on the development of products
based on molecules that present themselves at the T cell interface.
Through our knowledge and understanding of T cells, Avidex is able to
manipulate the key components of T cell activation. As a private
company, headquartered in Oxford, UK, Avidex has 55 employees.

Company:  BioSante Pharmaceuticals, Inc.
Ticker Symbol: BISP
Media Contact: Stephen M. Simes
Investor Relations Contact: Phillip Donenberg
Phone: [phone] ext 101
E-mail:  [e-mail]
Company URL:  www.biosantepharma.com

Product description:

   -- LibiGel(TM) -- testosterone gel for treatment of female sexual
      dysfunction.

   -- Bio-T-Gel(TM) -- testosterone gel for treatment of men.

   -- Bio-E-Gel(TM) -- estradiol gel for menopausal symptoms.

   -- Plus various combinations of estradiol, progestin and
      testosterone, all in topical gel formulations.

   -- Bio-Vant(TM) -- vaccine adjuvant.

   -- CAP-Oral(TM) -- for oral administration of therapies that
      currently must be injected.

Company Description: BioSante is an emerging pharmaceutical
company developing a comprehensive product line of hormone therapies
to treat men and women, including menopausal symptoms, female sexual
dysfunction and male testosterone deficiency. The company also is
developing a proprietary technology for improved vaccines, drug
delivery systems and the production of biotechnology products.

Company:  BioVex Limited
Workshop:  Immunology/Oncology
Media Contact:  Gareth Beynon
Investor Relations Contact:  Philip Astley-Sparke
Phone:  [phone]
E-mail:  [e-mail]
Company URL: www.biovex.com

Company description: BioVex is a four year old private UK biotech
company developing therapeutics for cancer and chronic infectious
disease. The Company has two product platforms (OncoVEX and ImmunoVEX)
and a functional genomics platform all based on the manipulation of
the herpes simplex virus. The Company's collaborations include Wyeth,
GlaxoSmithKline, AstraZeneca and Aventis.

Product description: OncoVEX(gm-csf) is a potent oncolytic vaccine
designed to treat solid tumours and their metastatic deposits.
Preliminary Phase I/II results have shown the product to be well
tolerated and significant biological effects have been observed. Phase
II trials are scheduled for Q2 2004. ImmunoVEX is a dendritic
cell-based vaccine platform. A Phase II trial in malignant melanoma is
scheduled to commence in Q4 2004.

Company: BTG
Ticker Symbol: (LSE:BGC)
Workshop: Small-Cap & Listed
Media Contact: Colleen Henry, 610-943-3540, [e-mail]
Investor Relations Contact: Andy Burrows, [phone],
[e-mail]
Phone: [phone]
E-mail: [e-mail]
Company URL: www.btgplc.com

Company description: BTG finds, develops and commercializes
emerging technologies in the life and physical sciences. These
innovations are protected by a strong portfolio of intellectual
property that BTG develops and enhances. BTG then captures the value
in these technologies through licensing and venturing activities. From
the origins of its business in 1949, BTG has commercialized major
innovations such as Magnetic Resonance Imaging (MRI), recombinant
factor IX blood-clotting protein, Campath(R) (alemtuzumab) and
Multilevel Cell (MLC) memory. BTG is quoted on the London Stock
Exchange under the symbol "BGC" and operates from offices in London
and Philadelphia, with representation in Tokyo. BTG operates through
wholly owned subsidiaries, BTG International Ltd. and BTG
International Inc. in the UK and USA, respectively. Further
information on BTG can be found at www.btgplc.com.

Company: Cantion A/S
Workshop: Medical Devices & Diagnostic
Media Contact: Carsten Faltum
Investor Relations Contact: Christian B. Kjaer
Phone: + 45 45 25 64 25
E-mail: [e-mail]
Company URL: www.cantion.com

Product description: Cantion manufactures and develops biochips
for label-free detection. The technology can be used for detection of
antigen-antibody, DNA and various other molecules. Cantion's
technology is based on micro cantilevers and can be used both as a
stationary instrument in laboratories and as a handheld device.

Company description: The Company was established in October 2001
and currently has 6 employees. During the first year Cantion developed
a biochip for label-free detection and an instrument with a
sensitivity equal to or better than normal ELISA tests. The first
products are ready for sale beginning 2003.

Company:  Coley Pharmaceutical Group
Media Contact: Robert Forrester
Investor Relations Contact: Robert Forrester
Phone: [phone]
E-mail:  [e-mail]
Company URL:  www.coleypharma.com

Company description: Coley Pharmaceutical Group is developing
several classes of targeted immunoregulatory drugs with broad
potential applications in cancer, asthma, allergy and infectious
diseases. Coley's CpG drug candidates activate the human immune system
to prevent or fight disease. Coley has 16 Phase I and Phase II
clinical trials completed or ongoing. Coley's lead product candidate,
CpG 7909, is in clinical trials as a monotherapy for melanoma and
renal cell carcinoma, and in combination with Rituxan(R) for
non-Hodgkin's B-cell lymphoma and with Herceptin(R) for breast cancer.
Coley has established a novel Human Cell Screening drug discovery and
development platform for the rapid validation and optimization of new
product candidates. Coley has product development and licensing
agreements with Aventis Pharmaceuticals, Inc. for the development of
CpG products in the treatment of asthma and allergic rhinitis, as well
as two license agreements with GlaxoSmithKline for the use of certain
CpG drug candidates in specified preventive and therapeutic infectious
disease vaccines and certain therapeutic cancer vaccines. Coley's
patent portfolio includes 65 U.S. patents and patent applications and
their worldwide counterparts, including ten U.S. patents that have
been issued. Coley is a private company with operations in the United
States, Germany and Canada. For further information, please visit
www.coleypharma.com.

Company: ConjuChem Inc.
Ticker Symbol: cjc
Workshop: Small-Cap / Listed Company Presentations
Media Contact: [e-mail]
Investor Relations Contact: [e-mail]
Phone: [phone]
E-mail: [e-mail]
Company URL:  www.conjuchem.com

Product description: DAC(TM) technology provides ConjuChem with the
ability to harness peptides as therapeutic agents by significantly
prolonging their half-lives. This proprietary technology has the
potential to create significant value for ConjuChem shareholders by
applying it to multiple drugs in a variety of therapeutic fields
including diabetes, cancer, AIDS, and many more.

Company description: ConjuChem has developed proprietary
technologies (DAC(TM) technology) that enable the rapid creation of
improved, patentable new drugs from existing drugs with
non-commercializable peptides. This technology when applied to a drug
compound, can create a new drug with similar therapeutic activity but
with a significantly longer duration of activity in the body than
conventional medications and an enhanced safety profile.

Company: DeveloGen AG
Ticker Symbol:  private
Workshop: Therapeutics;  Presentation: Dr. Gunther Karmann, CEO
Media Contact: Susanna Braus-Stromeyer
Investor Relations Contact: Carsten Dehning
Phone: [phone]
E-mail: [e-mail]
Company URL: www.develogen.com

Company description: DeveloGen is a biology based drug discovery
company developing novel therapies for metabolic disorders based on
extensive model organism and stem cell expertise. By starting with
metabolic phenotype, the company's model organism screens are more
rapid and disease relevant than conventional functional genomics
methods. The second component of DeveloGen's platform is focused on
harnessing key developmental control genes involved in stem cell
differentiation and tissue regeneration. By combining the strengths of
two platform technologies, DeveloGen has established a pipeline of
more than 30 highly validated targets for obesity and diabetes.
Currently 3 targets are in the drug discovery process. The management
team has secured a strong financial position for the company by
raising over EUR 60m to date. DeveloGen started operations in 1998 and
has currently over 100 employees located in Gottingen, Germany.

Company:  Dimethaid Research Inc.
Ticker Symbol: TSX:DMX
Media Contact:  Jodi Peake
Investor Relations Contact:  Jodi Peake
Phone: [phone]
E-mail: [e-mail]
Company URL:  www.dimethaid.com

Product description: Dimethaid is introducing North America's
first, prescription, topical nonsteroidal anti-inflammatory drug
(NSAID) for treating osteoarthritis. The drug uses a patented
transcellular carrier to deliver medication through the skin, directly
to the affected site. Dimethaid is also developing a second technology
platform based on immune regulation.

Company description: Dimethaid Research Inc. is a fully integrated
specialty pharmaceutical company headquartered in Canada with
subsidiaries in Europe, Asia and the Caribbean. The company develops,
manufactures and distributes therapeutic products designed to work
without causing the side effects associated with traditional
medications.

Company:  GB Therapeutics Ltd.
Workshop: Therapeutics
Media Contact:  Anthony Giovinazzo
Phone: [phone]
E-mail: [e-mail]
Company URL:  www.gbtherapeutics.com

Product description: GB Therapeutics has engineered novel nitrate
chemical entities with Central Nervous System selectivity that
function as "Smart Nitrates" in the Nitric Oxide processing pathway. A
product pipeline with multiple therapeutic indications has been
developed for the treatment of mild cognitive impairment, vascular
dementia, epilepsy, pain and for cardioprotection. Lead molecule GB
1061 is targeted at Alzheimer's disease and is expected to start a
Phase 1 study in man, in 2004, followed by a Phase IIa study in early
2005.

Company description: GB Therapeutics is at the forefront of new
research relating to the cell-protecting properties of nitric oxide.
Our mission: to become the leading international pharmaceutical
development company using novel proprietary nitrate drugs for the
treatment of key diseases of aging, with a focus on protecting the
central nervous system (CNS).

Company: IGENEON
Media Contact: Ursula Mayer
Phone: [phone]
E-mail: [e-mail]
Company URL: www.igeneon.com

Company description: igeneon is a biopharmaceutical company based
in Vienna, Austria which focuses on cancer immunotherapies. It has
built up a diversified portfolio consisting of three lead products
with broad applicability in clinical trials up to phase II/III as well
as a number of innovative follow up projects.The company is privately
held. Investors include 3i, Novartis Venture Fund and DVC.

Product description: igeneon's products are based on active and
passive immunization approaches. Common to all is the fact that they
use key mechanisms of the immune system to attack tumor cells. The
targets are tumor associated antigens which are frequently expressed
on epithelial cancers. The latter represent 70% of all cancer cases.
igeneon's goal is to combat disseminated tumor cells, thereby
preventing or delaying the formation of metastases, retarding the
further spread of the disease and extending cancer patients' life span
whilst maintaining their quality of life.

Company: Immunicon Corporation
Workshop: Immunology/Oncology
Media Contact: Edward L. Erickson
Investor Relations Contact: James G. Murphy
Phone: [phone]
E-mail: [e-mail]
Company URL: www.immunicon.com

Product description: Immunicon's principal focus is on the
development of innovative cellular analysis products for the
diagnosis, staging and monitoring of cancer. Advanced Diagnostic and
Cellular Systems (ADCS) division of Ortho-Clinical Diagnostics, Inc.,
a Johnson & Johnson company, has exclusive marketing rights to
Immunicon's technology in the cancer field.

Company description: Immunicon Corporation is a biomedical
products company that has developed a revolutionary diagnostic
platform based on selection and characterization of rare cells in
blood. Immunicon's technology is broadly applicable to medical
diagnostics, drug development and life science research. The Company
received its first regulatory clearance from the FDA in 2002.

Company: Ipsat Therapies Ltd
Workshop: Therapeutics
Media Contact: Marion Carson
Phone: [phone]
E-mail: [e-mail]
Company URL: www.ipsat-ther.com

Product description: Ipsat Therapies is developing recombinant
forms of beta-lactamases which are orally formulated and designed to
reduce hospital infections and antibiotic resistance, two of the most
serious side-effects resulting from the use of antibiotics. The
products are designed to target the beta-lactam class of antibiotics,
and achieve their effect by inactivation of unabsorbed beta-lactam
antibiotic fraction in the intestine, thus maintaining the normal
intestinal microflora during concurrent antibiotic administration.

Company description: Ipsat Therapies is a private innovative
Finnish biotechnology company focused on the development of
proprietary therapies which will be the first pharmaceutical products
aimed at preventing the emergence and spread of infections in hospital
and community while curbing the rise in antibiotic resistance. The
Company became operational in 1999 and its first product is in
clinical trials. The most important patient groups likely to benefit
from such treatment are the elderly, those on chronic antibiotic
treatment, and the immunosuppressed.

Company: ISOGENIS Inc.
Workshop: Therapeutics
Media Contact: Uwe D. Staerz
Phone: [phone]
e-mail: [e-mail]
Investor Relations Contact: John R. Price
Phone: [phone]
E-mail: [e-mail]
Company URL: www.isogenis.com

Product description: ISOGENIS' patented engineered veto technology
allows the production of versatile and adaptable vehicles of
long-lasting highly specific immune suppression thus preserving the
protective functions of the immune system. ISOGENIS is developing
human therapeutics for the prevention of transplant rejection, the
facilitation of gene therapy and the treatment of autoimmune diseases.

Company description: ISOGENIS is a development-stage biotechnology
company dedicated to designing a novel class of immune suppressive
drugs. The Company holds exclusive rights to its engineered veto
technology. It has successfully attracted over $ 2.1 million in
Federal research contracts and receives licensing payments for a
different technology, its cancer treating technology.

Company: Lorantis Ltd
Workshop: Immunology / Oncology
Contact:  Mark Bodmer
Phone: [phone]
E-mail: [e-mail]
Company URL: www.lorantis.com

Product description: Lorantis scientists have made a breakthrough
discovery of a fundamental mechanism controlling the immune system.
The technology allows suppression of the immune response to any chosen
antigen, while retaining the normal function of the rest of the immune
system. Antigen-specific modulation of the immune response will
revolutionise the treatment of immune disorders. Lorantis is
developing a new class of biopharmaceutical protein and DNA medicines
with the potential to transform the treatment of a broad range of
major diseases affecting millions of patients in markets worth
billions of dollars.

Company description: Lorantis is discovering and developing
breakthrough medicines for selective treatment of immunological
diseases. The company began operations in 2000 and has raised a total
of $28 million in venture backing from Abingworth Management, Schroder
Ventures, JP Morgan Partners, Quester, The Wellcome Trust and Northern
Venture Managers. Lorantis is based in Cambridge, UK, with a staff of
48.

Company: MacroPore Biosurgery
Ticker Symbol: XMP (Frankfurt Stock Exchange in Germany)
Media Contact: Christopher J. Calhoun
Investor Relations Contact: Ari Bisimis
Phone: [phone]
E-mail: [e-mail]
Company URL: www.macropore.com

Product description: Bioresorbable polymer surgical implants which
are naturally resorbed and metabolized by the body. Hydrosorb(TM)
bioresorbable products, used for spinal and reconstructive
indications, are distributed by Medtronic. SurgiWrap(TM) bioresorbable
thin film is used for soft tissue support. Through its biologics
technology, the company isolates adult stem cells from adipose (fat)
tissues.

Company description: With headquarters located in San Diego, CA,
MacroPore Biosurgery develops and markets products categorized in the
biosurgery market. Biomaterials platform technology includes
bioresorbable products that aid in the reconstruction, repair and
regeneration of bone and soft tissue throughout the body, and
biologics (stem cells) represent a second platform technology.

Company:  Maxcyte, Inc.
Workshop:  Therapeutics
Media Contact:  Eric Richman
Investor Relations Contact:  Joseph Lehnen
Phone:  [phone]
E-mail:  [e-mail]
Company URL:  Www.maxcyte.com

Product description: The MaxCyte GT clinical, non-viral cell
loading platform is being developed for therapeutic and
biopharmaceutical R&D applications. Products include immunotherapy for
CLL (PI), breast cancer, melanoma, cell therapy for congestive heart
failure and pulmonary diseases including pulmonary arterial
hypertension. R&D programs include drug discovery and
biopharmaceutical production.

Company description: MaxCyte, Inc. is commercializing the most
efficient and customizable cell loading technology available today.
MaxCyte's pipeline includes one therapeutic in Phase I and numerous
late stage pre clinical therapeutic candidates in oncology,
cardiovascular and genetic diseases. MaxCyte is enabling and improving
non-viral therapeutic gene transfer, identifying more targeted ways to
deliver drugs, and accelerating the drug discovery process.
Biopharmaceutical Research and development applications include high
throughput drug discovery, biopharmaceutical production and clinical
monitoring.

Company: Merrimack Pharmaceuticals
Workshop: Genomics & Proteomics
Media Contact: Tad Stewart
Investor Relations Contact: James S. Scibetta
Phone: [phone]
E-mail: [e-mail]
Company URL: www.MerrimackPharma.com

Company description:  Merrimack Pharmaceuticals is a private
biotechnology company dedicated to the development of novel
therapeutics for the treatment of autoimmune disease and cancer. Based
in Cambridge, Massachusetts the Company is a pioneer in the
application of Network Biology to commercial drug discovery.
Merrimack's emerging pipeline includes a potential blockbuster in the
early stages of clinical development.

Product description:  Merrimack's strategic advantage is its
expertise in the biology of immunology and cancer supported by a
proprietary, first of its kind technology platform that enables the
high-throughput analysis and modeling of complex biological networks.
While traditional drug discovery has focused on individual protein
targets, Merrimack's Network Biology approach leverages the high
throughput characterization of functional cellular pathways into true
network-based drug discovery.

Company:  MethylGene, Inc.
Workshop:  Immunology/Oncology
Media Contact:  Toni Rinow
Phone:  [phone]
Email:  [e-mail]
Company URL:  www.methylgene.com

MethylGene has an anticancer compound in clinical trials in the US
and Europe for solid and hematological tumors, with corporate partners
MGI Pharma and British Biotech, and anticipates an IND filing for a
small molecule anticancer compound at the end of this year. In
addition, their pipeline is filled with several compounds in
preclinical development in oncology and infectious disease.

MethylGene is engaged in the discovery and development of novel
inhibitor drugs that inhibit enzyme targets for the treatment of
cancer and infectious disease. Their drug discovery is structured
around use of functional genomics, rational drug design, and medicinal
chemistry to design, synthesize, and optimize inhibitor compounds
against validated enzyme targets.

Company:    MICROSCIENCE LIMITED
Media Contact:    JEAN GARON PR, [phone],
[e-mail]
Investor Relations:  Jonathan Pockson
Phone:  [phone]
E-mail:   [e-mail]
Company URL:     www.microscience.com

Product description: Microscience has used proprietary functional
genomics and vaccine technology expertise as the basis of an expanding
product portfolio. Microscience has five vaccines in development - 3
oral vaccines and 2 injectable protein subunit vaccines:

Oral Typhoid Vaccine, Neonatal Group B Streptococcus (GBS)
Vaccine, Meningitis B Vaccine, Oral Travellers' Diarrhoea (ETEC)
Vaccine and an Oral Hepatitis B Therapeutic Vaccine

Company description: Microscience is a biotechnology company
focused on the research and development of innovative,
rationally-designed vaccines for the prophylaxis and treatment of
disease particularly in areas of significant commercial value.
Microscience was founded in 1997 and is based near London, UK. The
Company's IP - with eight granted patents and more than a dozen other
patent families covering over 300 genes and targets - underpins the
product development programs.

Company: MithraGen, Inc.
Workshop: Immunology/Oncology
Media Contact: David Anderson
Phone: [phone]
E-mail: [e-mail]
Company URL: www.mithragen.com

Product description: MithraVax(TM) vaccines efficiently cross-present
antigens to both MHC class I and II and have demonstrated the ability
to more effectively activate T helper cells and induce an enhanced CTL
response and antibody response. In preclinical studies, MithraVax
vaccines have significantly inhibited tumor growth and substantially
prolonged animal survival.

Company description: MithraGen is developing innovative
immunotherapies for cancer and infectious diseases using its
proprietary vaccine platform, MithraVax(TM). MithraVax is designed to
optimize the functions of T and B cells and turn antigens containing
class I and class II epitopes into potent therapeutic vaccines capable
of inducing a complete antigen-specific immune response.

Company: Neurobiological Technologies, Inc.
Ticker Symbol:  ntii
Media Contact:    Ronny Kraft
Phone:    [phone] ext. 301
E-mail:    [e-mail]
Company URL:   www.ntii.com

Product Description:

Memantine - a potential neuroprotectant or neuromodulatory drug to
treat progressive neurological impairment due to neuronal injury, an
orally-available compound that acts to modulate the
N-methyl-D-aspartate ("NMDA") receptor in the central nervous system.
Modulating the NMDA receptor may restore functional neuronal
impairment associated with a number of disorders, including chronic
conditions of neuropathic pain, dementia, and Alzheimer's disease, and
acute conditions of traumatic brain injury and stroke.

XERECEPT(TM) - the company's synthetic preparation of the natural
human peptide CRF. In preclinical studies, XERECEPT(TM) has been
demonstrated to be an inhibitor of swelling, or edema. The compound is
being developed for its ability to reduce peritumoral brain edema.

Company Description: NTI is an emerging drug development company
focused on the clinical development and regulatory approval of
neuroscience drugs. The company develops neuroprotective and
neuromodulatory agents to treat progressive neurological impairments
characteristic of various nervous system disorders, including diabetic
neuropathy, brain cancer and AIDS dementia syndrome.

Company:  NewBiotics, Inc.
Contact:  Thomas Mizelle
Phone:        [phone]
Company URL:  www.newbiotics.com

NewBiotics is a biopharmaceutical company applying its proprietary
Enzyme Catalyzed Therapeutic Activation (ECTA) technology to create
new drugs to treat cancer and infectious disease. Based on
understanding disease at the molecular level and how enzymes are
regulated in response to genetic instability and disease progression,
NewBiotics' focus is to discover, develop and commercialize a new
generation of pharmaceuticals that transform drug resistance into
therapeutic advantage.

Our initial programs are focused on the development of small
molecules with novel mechanisms of action against relevant therapeutic
targets for the treatment of cancer and infectious disease. These
programs, all based on our proprietary ECTA(TM) technology, have
enabled us to generate a pipeline of compounds ranging from early
discovery through clinical development.

Company: NexMed, Inc
Ticker Symbol NEXM
Workshop: Small Cap/Listed Company Presentations
Media Contact: Deborah Carty
Phone: [phone] x 159
E-mail: [e-mail]
Company URL: www.nexmed.com

Product description: NexACT- a drug delivery technology offering
significant product development versatility and benefit.

NexMed's products in development are based on NexACT, its
proprietary platform technology. NexACT is a patented skin permeation
technology that enables rapid absorption of high concentrations of
active drug while reducing the side effects frequently attributed to
systemic medications. NexMed's development pipeline include Alprox-TD,
a cream treatment for male erectile dysfunction, NX100060 a
anti-fungal nail laquer, NM02216, a cream treatment for premature
ejaculation and Femprox, a cream treatment for female sexual arousal
disorder.

Company description: NexMed, Inc. is an emerging global
biopharmaceutical developer of innovative topical treatments based on
its proprietary delivery technologies. Our mission is to commercialize
innovative therapeutic solutions, through proprietary technologies in
order to fulfill unmet important medical needs and improve quality of
life.

Company: PanGenex, Inc.
Workshop: Post-Genomics
Media Contact: Candice Douglass
Investor Relations Contact: Leah Grant
Phone: [phone]
E-mail: [e-mail]
Company URL: www.pangenex.com

Product description:

Gene Knockouts with Human Cells: PanGenex has produced an
extensive library of gene knockout vectors that are exceptionally
efficient at producing gene knockouts with human cells. Such gene
knockout cells are predictive for effects of "perfect drugs" and are
screened to prioritize and identify the most effective drug discovery
targets.

Company description: PanGenex, Inc., a privately funded subsidiary
of Cell Therapeutics, Inc. (CTI), was founded in June 2000. CTI owns
approximately two-thirds of company shares with the remainder owned by
PanGenex employees. PanGenex is located at 201 Elliott Ave West, Suite
400, Seattle, WA 98119.

Company: Predix Pharmaceuticals, Inc.
Media Contact:  Michael Kauffman and/or Connie A. Lavoie
Phone:  [phone] ext. 13 or 781.376.0821 ext. 11
E-mail:  [e-mail]  or [e-mail]
Company URL: www. predixpharm.com

Product & Company Description: Predix Pharmaceuticals is an
integrated computational and medicinal chemistry company focused on
the development of novel drugs against G protein coupled receptors
(GPCRs). Predix is the only company in the world able to model the 3
dimensional structure of any GPCR whose ligand is known, and the
company has developed algorithms for in silico screening of any
chemical library against these structures.  Based on this technology
suite, Predix has obtained novel, nanomolar-affinity, drug-like lead
molecules against 4 of 5 tested GPCR programs (NK1, HT4, HT1A, D2,
CCR3).  Predix has created a suite of lead optimization algorithms
allowing parallel improvements in selectivity, oral bioavailability,
toxicology, and other properties.  Predix expects to be in clinical
trials within 1 year.

Company: ProSkelia
Workshop: Therapeutics
Media Contact: Philippe BALLERO
Phone: [phone]
E-mail: [e-mail]

Company and product description: ProSkelia, spun off from Aventis
in July 2002, is specialized in osteoporosis and related areas.
Osteoporosis is the second health problem after cardiovascular
diseases. ProSkelia has three products in clinical development as well
as three advanced and three early projects in pre-clinical.

--Trimpatch: new potent progestin + estradiol patch for menopausal
symptoms and osteoporosis. No androgenic activity. Phase III.

-- PSK 3841: first topical anti-androgenic for alopecia and acne.
Metabolized very rapidly. Phase I-IIA.

--PSK 3471: Selective Estrogen Receptor Modulator for osteoporosis.
Unlike other SERM's, PSK 3471 is designed not to induce hot flushes.
Phase I.

Company: RiboTargets Ltd
Workshop: Immunology/Oncology
Contact: Donna Washtell
Phone: [phone]
E-mail: [e-mail]
Company URL: www.ribotargets.com

Company description: RiboTargets discovers therapeutics to treat
patients with bacterial infections and patients with cancer. The
Company has established an innovative drug design and development
engine that enhances and accelerates the drug discovery process.

Company: Scandinavian Micro Biodevices A/S (SMB)
Workshop: Medical devices / Diagnostics
Media Contact: Ole Kring
Investor Relations Contact: Christian B. Kjaer
Phone: [phone]
E-mail: [e-mail]
Company URL: www.smb.dk

Product description: The Excelerator(R) service integrates and
streamlines all the technologies required to mass manufacture
biochips. SMB also offers a proprietary plasma surface modification
technology SoftPlasma(R) that enables us to produce a number of
surfaces with hydrophobic/-philic, cytofobic/-philic and binding
properties for DNA, proteins and cells. SMB also market a ready to
spot slide SpotOn(R) for aminated oligos and proteins.

Company description: SMB is a 3 year old company with 14 employees
and a business strategy of becoming leading OEM manufacturer of
biochips. SMB is working with customers on development projects in
Europe and the US expecting a turnover of approx. 1 million USD for
2003. If successful these customers expect to start mass production
late this year or early 2004.

Company:  Stressgen Biotechnologies Corporation
Ticker Symbol:  TSX:SSB
Workshop:  Small Cap Session
Media Contact:  Donna Slade, 858.202.4945
Investor Relations Contact:  Jennifer Matterson
Phone:  [phone]
E-mail:  [e-mail]
Company URL:  www.stressgen.com

Product description: The company's lead product, HspE7, is in
Phase II and Phase III clinical trials for the treatment of patients
with conditions caused by the human papillomavirus (HPV), including
anal dysplasia and recurrent respiratory papillomatosis (RRP). HspE7
may also have applications in other indications caused by HPV,
including genital warts, cervical dysplasia and cervical cancer.

Company description: Stressgen is focused on the discovery,
development, and commercialization of innovative, proprietary
CoVal(TM) fusion therapeutics for the treatment of infectious disease
and cancer. The company's proprietary platform technology is based on
the fusion of a stress protein, also called a heat-shock protein
(HSP), and a disease-specific protein (antigen). Hsp fusion proteins
can invoke a potent and targeted immune response.

Company: The Genetics Company, Inc.
Workshop: Oncology
Media Contact: Dietmar Gundel
Investor Relations Contact:  Andreas Ziegler
Phone: [phone]
E-mail: [e-mail]
Company URL: www.the-genetics.com

Product description:

Colon Cancer: Small molecules inhibitors of the Wnt-pathway that
block the growth of human colon cancer cell lines.

Alzheimer's Disease: Small molecule inhibitors of "BACE" have been
generated. BACE is perceived as the most promising target for the
treatment of this disease. Furthermore, in vivo and in silico
validation and screening services are offered.

Company description: The Genetics Company is a drug discovery and
development company active in the areas of cancer and
neurodegenerative diseases. The Company has generated a set of small
molecules that have the potential to significantly improve the
therapies of (colorectal) cancer and Alzheimer's disease. These
opportunities result from the Company's unique combination of
proprietary in silico and in vivo technologies.

Company: TolerRx, Inc.
Workshop: Therapeutics
Media Contact: Douglas E. Onsi
Investor Relations Contact: Douglas E. Onsi
Phone: [phone]
E-mail: [e-mail]
Company URL: www.tolerrx.com

Product description: TolerRx, Inc. has four antibody products in
development. TRX1 is being developed in collaboration with Genentech,
Inc. and will be used to induce immunological tolerance. TolerRx
initiated a Phase I study in the UK with TRX1 in November, 2002. TRX4
is being developed to treat patients with new onset Type I diabetes,
and is currently being used in an investigator-sponsored clinical
trial in Europe. TRX3 is a TolerMab(TM) antibody being developed for
use in autoimmune diseases. TRX4 is a humanized monoclonal antibody
being developed for use in transplantation.

Company description: TolerRx is a biopharmaceutical company
specializing in the discovery and development of novel therapies that
induce, maintain, or remove immunological tolerance. The Company has
established research, discovery, and clinical development programs
aimed at providing novel therapies which reprogram the immune system
to treat patients with immune-mediated diseases. These therapies are
designed to benefit patients by providing long-term efficacy, shorter
treatment regimes, and superior safety profiles.

Company: Trigen Ltd
Workshop: 11.00 Sector Workshops on 21 March 2003
Media Contact: Katharine Harris
Phone: [phone]
E-mail: [e-mail]
Company URL:  www.trigen.co.uk

Product description: Trigen has two products in clinical trials
from its lead thrombin inhibitor programme; an intravenous formulation
of the lead molecule TRI 50b in Phase II and an oral formulation of
TRI 50b which is in Phase I. Both formulations are potentially
effective in venous and arterial indications. Extensive pre-clinical
and clinical trials have been completed for both the intravenous and
oral formulations. Evidence from these studies suggests that TRI 50b
is potentially more effective than currently available
anti-coagulants, with a wide therapeutic index, a low bleeding
tendency and potentially no monitoring requirement. Trigen's thrombin
inhibitor could therefore enjoy a valuable competitive advantage over
existing anti-coagulant agents and those in clinical development for
use in the acute, hospital-based setting but also, more importantly,
in the long-term outpatient setting where the "blockbuster" market
opportunity lies. These attributes make Trigen's thrombin inhibitor
programme a highly-attractive potential in-licensing clinical asset
for major pharmaceutical and biotechnology companies.

Company description: Trigen is a private UK biotechnology company,
based in London, developing novel drugs for the treatment of
cardiovascular diseases, with a focus on thrombosis. Trigen has two
products in clinical trials from its lead drug development programme:
an intravenous and oral formulation of an anti-coagulant, direct
thrombin inhibitor. In addition, Trigen has other programmes focused
on atheroma, thrombosis and inflammation in discovery/pre-clinical
development. Trigen was founded in 1992 to invest in and develop the
drug discovery technologies of the world-renowned Thrombosis Research
Institute (TRI) in London.

Note to media: To register for a free, custom news feed via Business Wire's Press Pass, go to http://www.tradeshownews.com/ifmd/ifmd-regpress.html.

Note to exhibitors: Information about Business Wire's global trade show news distribution options is available at http://www.tradeshownews.com/tsn/index4.html.

To issue your trade show or conference news, contact your local Business Wire bureau at 888/381-9473.